When is an SGLT2 inhibitor indicated for heart failure?

• A. With or without type II DM to reduce hospitalizations and adverse cardiac events
• B. Only for HF with EF < 40%
• C. Only in patients with type I DM
• D. For controlling blood glucose exclusively

Answer: (A)

SGLT2 inhibitors improve heart failure outcomes beyond glucose lowering, reducing hospitalizations for heart failure and cardiovascular events, and these benefits apply whether or not a patient has type 2 diabetes.

This is why the option stating they can be used in heart failure with or without type 2 diabetes to lessen HF hospitalizations and adverse cardiac events is the best. Trials like DAPA-HF and EMPEROR-Reduced showed clear reductions in HF hospitalizations and cardiovascular death in patients with HFrEF, and later evidence also supports benefit in HFpEF. They’re not limited to a specific EF cut-off, they’re not restricted to type I diabetes, and they’re not used solely to lower blood glucose—the cardiovascular benefits are central to their indication in heart failure.